The estimated @-month progression-free-survival rates were @ % for pembrolizumab every @ weeks , @ % for pembrolizumab every @ weeks , and @ % for ipilimumab ( hazard ratio for disease progression , @ ; P < @ for both pembrolizumab regimens versus ipilimumab ; @ % confidence intervals -LSB- CIs -RSB- , @ to @ and @ to @ , respectively ) .